Is Hepcidin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients?

Bratescu, Lavinia; Bârsan, Liliana; Munteanu, Dan; Sica, Simona; Mircescu, Gabriel

doi:10.1053/j.jrn.2010.06.006

Cited by 18 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum hepcidin was correlated positively with ferritin [5,29] and negatively with the dose of rhEPO [5], but failed to predict the response to rhEPO. However, lower serum levels of hepcidin [30] and ferritin [21,31] have been associated with increased resistance to rhEPO in HD patients. In contrast, our study showed a trend toward an increase of Hb after rhEPO in HD patients with low serum levels of hepcidin-25 and ferritin.…”

Section: Discussionmentioning

confidence: 99%

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients

Takasawa¹,

Tomosugi

Takaeda³

et al. 2014

Nephron Extra

View full text Add to dashboard Cite

Background/Aims: We examined whether regulation of hepcidin-25 by short- or long-acting recombinant human erythropoietin (rhEPO) is dependent on ferritin and predicts the response to rhEPO in hemodialysis (HD) patients. Methods: Two studies with rhEPO were performed in 9 HD patients with a 2-year interval. Serum hepcidin-25 was measured at 0-18 h after intravenous epoetin-β (EPO) or methoxy polyethylene glycol-epoetin-β (PEG-EPO) administration and on days 3-7 after PEG-EPO. Hemoglobin (Hb), serum ferritin, transferrin, C-reactive protein (CRP), and interleukin (IL)-6 were analyzed before hepcidin measurement and 6 months after rhEPO. Based on the serum ferritin levels before hepcidin measurement, the patients in the two studies with EPO or PEG-EPO were combined into low (11; serum ferritin of <15.0 ng/ml) and high ferritin groups (7; serum ferritin of ≥15.0 ng/ml). The response of hepcidin-25 to rhEPO and the effect of rhEPO on anemia were compared between the groups. Results: The serum hepcidin-25 levels rose at 6-9 h and returned to the baseline at 18 h after EPO. They rose at 6-9 h, returned to the baseline at 18 h, and decreased on day 5-7 after PEG-EPO. Serum hepcidin-25 levels were low (<5.0 ng/ml) in the low ferritin group, but rose at 6-9 h after rhEPO in the high ferritin group. Serum transferrin levels were similar, and CRP and IL-6 were normal in both groups. Hb tended to increase in the low ferritin group, but it significantly decreased in the high ferritin group after rhEPO. Conclusion: Regulation of hepcidin-25 by rhEPO may be dependent on ferritin, affecting the response to rhEPO in HD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients

Takasawa¹,

Tomosugi

Takaeda³

et al. 2014

Nephron Extra

View full text Add to dashboard Cite

show abstract

“…Moreover, we recently reported that frequent mutations in the HFE gene, which decrease hepcidin response to iron stores (Piperno, Girelli et al 2007;Vujic Spasic, Kiss et al 2008), are associated with increased sensitivity to ESAs and iron in CHD patients, and may be associated with a better clinical outcome (Valenti, Valenti et al 2008). However, in a preliminary report hepcidin-25 was not significantly associated with Epo responsiveness (Kato, Tsuji et al 2008), and in another recent study an association between greater iron doses, increased darbepoietin resistance index, and low hepcidin levels, possibly downregulated by ESAs and anemia, was detected (Bratescu, Barsan et al 2010), thus suggesting that other mechanisms besides increased hepcidin are involved in the pathogenesis of anemia in CHD. All in all, these recent studies suggest that hepcidin is involved in the pathogenesis of anemia in CKD and chronic diseases, but is not the only player involved.…”

Section: Role Of Hepcidin In Anemia Of Esrdmentioning

confidence: 96%

Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications

Canavesi¹,

Valenti²

2011

Hemodialysis - Different Aspects

View full text Add to dashboard Cite

“…One study revealed that hepcidin concentrations of EPO responders did not differ from those of hyporesponders (176 ), whereas crosssectional studies among HD patients and a prospective study among patients with combined CKD and chronic heart failure revealed that nonresponders had low hepcidin concentrations (32,170,177 ). Possibly hepcidin should be regarded as a marker of response rather than resistance to ESA treatment in these patients.…”

Section: Disorders Associated With Hepcidin Excessmentioning

confidence: 99%

Hepcidin in Human Iron Disorders: Diagnostic Implications

et al. 2011

View full text Add to dashboard Cite

BACKGROUND:The peptide hormone hepcidin plays a central role in regulating dietary iron absorption and body iron distribution. Many human diseases are associated with alterations in hepcidin concentrations. The measurement of hepcidin in biological fluids is therefore a promising tool in the diagnosis and management of medical conditions in which iron metabolism is affected.CONTENT: We describe hepcidin structure, kinetics, function, and regulation. We moreover explore the therapeutic potential for modulating hepcidin expression and the diagnostic potential for hepcidin measurements in clinical practice.

show abstract

Is Hepcidin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients?

Cited by 18 publications

References 27 publications

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients

Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications

Hepcidin in Human Iron Disorders: Diagnostic Implications

Contact Info

Product

Resources

About